This is an aggregated industry headline. Read the full story at FiercePharma →
EHA: J&J sharpens myeloma edge as Talvey, Darzalex Faspro combo proves its worth in earlier disease stage
J&J's MonumenTAL-3 phase 3 study of bispecific antibody Talvey and Darzalex Faspro in patients with earlier-stage multiple myeloma earned a plenary spot at the 2026 European Hematology Association annual meeting.
By FiercePharma
· Jun 13, 2026
· via FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Havas Lynx has shaken up the leadership of its New York team, expanding Claire Knapp's role to cover the offic…
The WeekFierceBiotech ↗
Rare disease biotech Oak Hill is headed to the Nasdaq through a SPAC merger with RA Capital-sponsored Research…
The WeekBriefing
FDA approval of Otsuka’s Simtriyo gives the company a first-in-class ADHD asset. The real question now is whet…